Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study.
Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study.
复制标题
DOI：
10.1007/s10072-020-04767-x
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Vernieri F
中科院分区：
文献类型：
--
作者：
Altamura C;Cevoli S;Aurilia C;Egeo G;Fofi L;Torelli P;Brunelli N;Pierangeli G;Favoni V;Fallacara A;Pensato U;Barbanti P;Vernieri F
COVID-19大流行和随之而来的封锁就像风暴一样扰乱了人们的日常生活。本研究旨在观察COVID-19相关的封锁是否会影响接受抑制CGRP通路的单克隆抗体治疗的偏头痛患者的偏头痛频率和残疾。在这项纵向观察性队列研究中，147例连续接受erenumab或galcanezumab每月给药的患者在4个意大利头痛中心入组。所有患者都填写了一份调查问卷，内容涉及工作和家庭环境、最近的流感症状或COVID-19诊断以及因COVID-19感染而失去的家庭。每月偏头痛天（MMD），每月止痛药摄入量（MPI），和HIT-6残疾相对于第一个月的封锁强加（T锁）和前一个月（T自由）也被收集。从无T型到T型锁定，该队列显示MMD（从10.5 ± 7.6降至9.8 ± 7.6，p = 0.024）和HIT-6评分（从59.3 ± 8.3）降低，男性比女性更频繁地降低MPI（p = 0.005）。 我们的研究观察到封锁的影响为57.8 ± 8.8，p = 0.009），而MPI结果没有变化（从11.6 ± 11.5到11.1 ± 11.7; p = 0.114）。MMD，MPI和HIT-6的变化，从T-无T-锁没有不同的工作环境或家庭。超过治疗的前3个月的患者较少出现MMD减少（p = 0.006），并且在日常生活中并不影响接受抑制CGRP通路的单克隆抗体的患者的偏头痛负荷。根据药物药代动力学，治疗前几个月的患者出现了更大的改善，而女性更频繁地需要急救药物，可能表明出勤或头痛恐惧症。
The COVID-19 pandemic and the consequent lockdown came as a storm disrupting people’s everyday life. This study aimed at observing whether the COVID-19 related lockdown influenced migraine frequency and disability in migraine patients on therapy with monoclonal antibodies inhibiting the CGRP pathway. In this longitudinal observational cohort study, 147 consecutive patients receiving monthly administration of erenumab or galcanezumab were enrolled in four Italian headache centers. All patients filled a questionnaire concerning working and household settings, recent flu symptoms or COVID-19 diagnosis, and family loss due to COVID-19 infection. Monthly migraine days (MMDs), monthly painkiller intake (MPI), and HIT-6 disability relative to the first month of lockdown imposition (T-lock) and the month before (T-free) were also collected. From T-free to T-lock, the cohort displayed a reduction in MMDs (from 10.5 ± 7.6 to 9.8 ± 7.6, p = .024) and HIT-6 scores (from 59.3 ± 8.3 men reduced MPI more frequently than women (p = .005). Our study observed that the lockdown impact to 57.8 ± 8.8, p = .009), while MPI resulted unchanged (from 11.6 ± 11.5 to 11.1 ± 11.7; p = .114). MMDs, MPI, and HIT-6 variations from T-free to T-lock did not differ according to work settings or household. Patients beyond the first 3 months of therapy presented less often a reduction in MMDs (p = .006) and on everyday life did not affect the migraine load in patients receiving monoclonal antibodies inhibiting the CGRP pathway. Patients in the first months of therapy experienced a greater improvement according to drug pharmacokinetics, while women more frequently needed rescue medications, possibly indicating presenteeism or cephalalgophobia.
登录
查看更多内容
DOI：
10.1186/s10194-016-0667-0
发表时间：
2016-12
期刊：
The journal of headache and pain
影响因子：
--
作者：
Santangelo G;Russo A;Trojano L;Falco F;Marcuccio L;Siciliano M;Conte F;Garramone F;Tessitore A;Tedeschi G
通讯作者：
Tedeschi G
影响因子：
5
作者：
Detke, Holland C.;Millen, Brian A.;Aurora, Sheena K.
通讯作者：
Aurora, Sheena K.
影响因子：
158.5
作者：
Goadsby, Peter J.;Reuter, Uwe;Lenz, Robert A.
通讯作者：
Lenz, Robert A.
影响因子：
7.4
作者：
Vo, Pamela;Fang, Juanzhi;Gupta, Shaloo
通讯作者：
Gupta, Shaloo
影响因子：
5
作者：
Black, Anna Katherine;Fulwiler, Joshua C.;Smitherman, Todd A.
通讯作者：
Smitherman, Todd A.